Projects / Programmes
NOVEL BIOTECH DRUG SUBSTANCES BY USING PHAGE DISPLAY TECHNOLOGY
| Code |
Science |
Field |
Subfield |
| 4.06.00 |
Biotechnical sciences |
Biotechnology |
|
| Code |
Science |
Field |
| T490 |
Technological sciences |
Biotechnology |
drug substances, Helicobacter pylori, peptides, bacteriophage display, Mur-ligases, lipids, 17-hydroxisteroid dehidrogenase
Researchers (15)
Organisations (2)
Abstract
The intensive development of modern pharmaceutical biotechnology in the last decade gives us the possibility to discover novel, specific biological drugs. One of the promising tools is bacteriophage display, where huge number of random peptides are exposed at the tip of bacteriophages and might bind to specific target protein. The principal aim of the proposed project is selection of specific bacteriophages with peptides that might represent strong inhibitors of bacterial enzymes Mur ligases, human pancreatic lipase and leptin, fungal 17 hydroxysteroid dehidrogenase as well as the ligands to Helicobacter pylori surface adhesins. From selected bacteriophages, DNA will be isolated from selected bacteriophages and subjected to nucleotide sequencing. Based on DNA sequence, peptides will be synthesized and tested on their ability to bind to the target proteins. Finally, successful candidates will represent the basic peptidic backbones for further development of peptidomimetics. In case of ligands of H. pylori adhesins, gene constructs will be made for expression of tightly bound peptidic ligands at the surface of Lactococcus lactis or Bifidobacterium bifidus in order to develop a functional probiotic against H. pylori intestinal growth.
Significance for science
In last decade we are faced with the real explosion of the explanation of molecular mechanisms between the complex of two affinity protein particles. These findings enable rapid progression of basic and applicative science in medicine, pharmacy, biotechnology and biology, in particular in the development of novel biopharmaceutical drugs or peptidomimetic small molecules with protein targets.
Within the frame of the project we succeded in the publication of several important scientific articles, we developed the alternative method for elution of bacteriphage clones from their protein targets and we developed the recombinant probiotic that might serve as a biodrug delivery system. Part of results already expose their applicative values. We believe that substantial part of the results will be expanded in a near future.
Significance for the country
Within the field of pharmaceutical science, knowledge and technology plays Republic of Slovenia an important role in central Europe. The most straitforward dvelopment was achieved in last several years in pharmaceutical company Lek by their R&D on the biopharamceutical field, in particular by the development of biosimilar drugs. Every additional expertize, R&D and technology might synergistically increase the influece and success of Slovenian economy in this field. Substantial part of our effort is focused on the contribution for further develope the filed of biopharmaceutcals and similar biological medical products (biosimilars). all these may even better improve the potential novel development, establish novel plants and enable inetgrity and personmal stability of employess within the biotech field.
Most important scientific results
Annual report
2008,
2009,
final report,
complete report on dLib.si
Most important socioeconomically and culturally relevant results
Annual report
2008,
2009,
final report,
complete report on dLib.si
